Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Gene therapy of hemoglobinopathies: progress and future challenges

Abstract

Recently, gene therapy clinical trials have been successfully applied to hemoglobinopathies, such as sickle cell disease (SCD) and β-thalassemia. Among the great discoveries that led to the design of genetic approaches to cure these disorders is the discovery of the β-globin locus control region and several associated transcription factors, which determine hemoglobin switching as well as high-level, erythroid-specific expression of genes at the ß-globin locus. Moreover, increasing evidence shows that lentiviral vectors are efficient tools to insert large DNA elements into nondividing hematopoietic stem cells, showing reassuring safe integration profiles. Alternatively, genome editing could restore expression of fetal hemoglobin or target specific mutations to restore expression of the wild-type β-globin gene. The most recent clinical trials for β-thalassemia and SCD are showing promising outcomes: patients were able to discontinue transfusions or had reduced transfusion requirements. However, toxic myeloablation and the high cost of current ex vivo hematopoietic stem cell gene therapy platforms represent a barrier to a widespread application of these approaches. In this review, we summarize these gene therapy strategies and ongoing clinical trials. Finally, we discuss possible strategies to improve outcomes, reduce myeloablative regimens and future challenges to reduce the cost of gene therapy platform.

Overview

Integrity signals

Registry

Crossref · 10.1093/hmg/ddz172

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Research works printed but not linked: 2

  1. Patel, 2016, CADTH Issues in Emerging Health Technologies
  2. Rasko, 2018, American Society of Hematology. American Society of Hematology, 132

Cited by

See all 88

Metadata

Authors
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • Inserm (FR)
  • Hôpital Necker-Enfants Malades (FR)
Corresponding author
Rivella, Stefano
Venue
Human Molecular Genetics
Published
2019-07-19
Volume
28
Issue
R1
Pages
R24-R30
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2964149073
Cited by
86
References
75
Citations by year
2026: 2 · 2025: 10 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 21 · 2020: 31 · 2019: 2
FWCI
1.99
Type
journal article
Language
en
Open access
closed
Locations
  • Human Molecular Genetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Agence Nationale de la Recherche (ANR-10-IAHU-01, ANR-16-CE18-0004)
  • European Union’s Horizon 2020 (693762-ERC-2015-AdG- GENEFORCURE)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
gene therapy, hemoglobinopathies, sickle cell disease, beta-thalassemia, beta-globin locus control region, hemoglobin switching, lentiviral vectors, hematopoietic stem cells, genome editing, fetal hemoglobin, myeloablation, ex vivo gene therapy, clinical trials, cost of gene therapy
MeSH terms
Animals, Clinical Trials as Topic, Gene Expression Regulation, Genetic Vectors, Hemoglobinopathies, Hemoglobins, Humans, Mutation, Transduction, Genetic, Genetic Therapy, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy of hemoglobinopathies: progress and future challenges. https://app.cochat.ai/papers/10.1093/hmg/ddz172
The paper
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019). Gene therapy of hemoglobinopathies: progress and future challenges. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddz172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.